661 related articles for article (PubMed ID: 24928805)
1. Long-term effectiveness of dopamine agonists and monoamine oxidase B inhibitors compared with levodopa as initial treatment for Parkinson's disease (PD MED): a large, open-label, pragmatic randomised trial.
; Gray R; Ives N; Rick C; Patel S; Gray A; Jenkinson C; McIntosh E; Wheatley K; Williams A; Clarke CE
Lancet; 2014 Sep; 384(9949):1196-205. PubMed ID: 24928805
[TBL] [Abstract][Full Text] [Related]
2. Long-term Effectiveness of Adjuvant Treatment With Catechol-O-Methyltransferase or Monoamine Oxidase B Inhibitors Compared With Dopamine Agonists Among Patients With Parkinson Disease Uncontrolled by Levodopa Therapy: The PD MED Randomized Clinical Trial.
Gray R; Patel S; Ives N; Rick C; Woolley R; Muzerengi S; Gray A; Jenkinson C; McIntosh E; Wheatley K; Williams A; Clarke CE;
JAMA Neurol; 2022 Feb; 79(2):131-140. PubMed ID: 34962574
[TBL] [Abstract][Full Text] [Related]
3. Cost-Effectiveness of Dopamine Agonists and Monoamine Oxidase B Inhibitors in Early Parkinson's Disease.
McIntosh E; Kent S; Gray A; Clarke CE; Williams A; Jenkinson C; Ives N; Patel S; Rick C; Wheatley K; Gray R;
Mov Disord; 2021 Sep; 36(9):2136-2143. PubMed ID: 33960511
[TBL] [Abstract][Full Text] [Related]
4. Evaluation of the efficacy and safety of adjuvant treatment to levodopa therapy in Parkinson s disease patients with motor complications.
Stowe R; Ives N; Clarke CE; Deane K; ; Wheatley K; Gray R; Handley K; Furmston A
Cochrane Database Syst Rev; 2010 Jul; (7):CD007166. PubMed ID: 20614454
[TBL] [Abstract][Full Text] [Related]
5. Real life evaluation of safinamide effectiveness in Parkinson's disease.
Mancini F; Di Fonzo A; Lazzeri G; Borellini L; Silani V; Lacerenza M; Comi C
Neurol Sci; 2018 Apr; 39(4):733-739. PubMed ID: 29441484
[TBL] [Abstract][Full Text] [Related]
6. Levodopa alone compared with levodopa-sparing therapy as initial treatment for Parkinson's disease: a meta-analysis.
Xie CL; Zhang YY; Wang XD; Chen J; Chen YH; Pa JL; Lin SY; Lin HZ; Wang WW
Neurol Sci; 2015 Aug; 36(8):1319-29. PubMed ID: 25981231
[TBL] [Abstract][Full Text] [Related]
7. Comparative effectiveness of dopamine agonists and monoamine oxidase type-B inhibitors for Parkinson's disease: a multiple treatment comparison meta-analysis.
Binde CD; Tvete IF; Gåsemyr JI; Natvig B; Klemp M
Eur J Clin Pharmacol; 2020 Dec; 76(12):1731-1743. PubMed ID: 32710141
[TBL] [Abstract][Full Text] [Related]
8. Monoamine oxidase B inhibitors versus other dopaminergic agents in early Parkinson's disease.
Caslake R; Macleod A; Ives N; Stowe R; Counsell C
Cochrane Database Syst Rev; 2009 Oct; (4):CD006661. PubMed ID: 19821381
[TBL] [Abstract][Full Text] [Related]
9. Cardiovascular and mortality risks in Parkinson's disease patients treated with entacapone.
Graham DJ; Williams JR; Hsueh YH; Calia K; Levenson M; Pinheiro SP; Macurdy TE; Shih D; Worrall C; Kelman JA
Mov Disord; 2013 Apr; 28(4):490-7. PubMed ID: 23443994
[TBL] [Abstract][Full Text] [Related]
10. [Dopamine agonists in Parkinson's disease therapy - 15 years of experience of the Neurological Clinics from Tîrgu Mureș. A cross-sectional study].
Szász JA; Viorelia C; Mihály I; Biró I; Péter C; Orbán-Kis K; Szatmári S
Ideggyogy Sz; 2019 May; 72(5-6):187-193. PubMed ID: 31241263
[TBL] [Abstract][Full Text] [Related]
11. Alternatives to levodopa in the initial treatment of early Parkinson's disease.
Lees A
Drugs Aging; 2005; 22(9):731-40. PubMed ID: 16156677
[TBL] [Abstract][Full Text] [Related]
12. [The role of selective monoamine oxidase B inhibitors in the therapeutic strategy of Parkinson's disease in the neurology clinics of Tirgu Mures County Emergency Clinical Hospital].
Szász JA; Constantin V; Fazakas PA; Blényesi E; Grieb LG; Balla A; Sárig M; Szegedi K; Bartha EN; Szatmári S
Orv Hetil; 2017 Dec; 158(51):2023-2028. PubMed ID: 29250969
[TBL] [Abstract][Full Text] [Related]
13. Treatment Strategies in Early Parkinson's Disease.
Marsili L; Marconi R; Colosimo C
Int Rev Neurobiol; 2017; 132():345-360. PubMed ID: 28554414
[TBL] [Abstract][Full Text] [Related]
14. Monoamine oxidase B inhibitors for early Parkinson's disease.
Macleod AD; Counsell CE; Ives N; Stowe R
Cochrane Database Syst Rev; 2005 Jul; 2005(3):CD004898. PubMed ID: 16034956
[TBL] [Abstract][Full Text] [Related]
15. What is the best initial treatment in Parkinson's disease?
Sharp ME; Mazzoni P
J R Coll Physicians Edinb; 2014; 44(4):291-2. PubMed ID: 25516899
[No Abstract] [Full Text] [Related]
16. Dopamine agonist therapy in early Parkinson's disease.
Stowe RL; Ives NJ; Clarke C; van Hilten J; Ferreira J; Hawker RJ; Shah L; Wheatley K; Gray R
Cochrane Database Syst Rev; 2008 Apr; (2):CD006564. PubMed ID: 18425954
[TBL] [Abstract][Full Text] [Related]
17. Initial choice of medication has little effect on short-term or long-term outcome for most patients with Parkinson's disease.
Hauser RA
Evid Based Med; 2015 Feb; 20(1):17. PubMed ID: 25525039
[No Abstract] [Full Text] [Related]
18. Pharmacological Treatment of Early Motor Manifestations of Parkinson Disease (PD).
Sy MAC; Fernandez HH
Neurotherapeutics; 2020 Oct; 17(4):1331-1338. PubMed ID: 32935299
[TBL] [Abstract][Full Text] [Related]
19. Cost effectiveness of rasagiline and pramipexole as treatment strategies in early Parkinson's disease in the UK setting: an economic Markov model evaluation.
Haycox A; Armand C; Murteira S; Cochran J; François C
Drugs Aging; 2009; 26(9):791-801. PubMed ID: 19728752
[TBL] [Abstract][Full Text] [Related]
20. Pramipexole vs levodopa as initial treatment for Parkinson disease: A randomized controlled trial. Parkinson Study Group.
Parkinson Study Group
JAMA; 2000 Oct; 284(15):1931-8. PubMed ID: 11035889
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
